Literature DB >> 32059667

"Point of no return" in unilateral renal ischemia reperfusion injury in mice.

Alexander Holderied1, Franziska Kraft2, Julian Aurelio Marschner2, Marc Weidenbusch2, Hans-Joachim Anders2.   

Abstract

BACKGROUND: In the past years evidence has been growing about the interconnection of chronic kidney disease and acute kidney injury. The underlying pathophysiological mechanisms remain unclear. We hypothesized, that a threshold ischemia time in unilateral ischemia/reperfusion injury sets an extent of ischemic tubule necrosis, which as "point of no return" leads to progressive injury. This progress is temporarily associated by increased markers of inflammation and results in fibrosis and atrophy of the ischemic kidney.
METHODS: Acute tubule necrosis was induced by unilateral ischemia/reperfusion injury in male C57BL/6 N mice with different ischemia times (15, 25, 35, and 45 min). At multiple time points between 15 min and 5 weeks we assessed gene expression of markers for injury, inflammation, and fibrosis, histologically the injury of tubules, cell death (TUNEL), macrophages, neutrophil influx and kidney atrophy.
RESULTS: Unilateral ischemia for 15 and 25 min induced upregulation of markers for injury after reperfusion for 24 h but no upregulation after 5 weeks. None of the markers for inflammation or fibrosis were upregulated after ischemia for 15 and 25 min at 24 h or 5 weeks on a gene expression level, except for Il-6. Ischemia for 35 and 45 min consistently induced upregulation of markers for inflammation, injury, and partially of fibrosis (Tgf-β1 and Col1a1) at 24 h and 5 weeks. The threshold ischemia time for persistent injury of 35 min induced a temporal association of markers for inflammation and injury with peaks between 6 h and 7 d along the course of 10 d. This ischemia time also induced persistent cell death (TUNEL) throughout observation for 5 weeks with a peak at 6 h and progressing kidney atrophy beginning 7 d after ischemia.
CONCLUSIONS: This study confirms the evidence of a threshold extent of ischemic injury in which markers of injury, inflammation and fibrosis do not decline to baseline but remain upregulated assessed in long term outcome (5 weeks). Excess of this threshold as "point of no return" leads to persistent cell death and progressing atrophy and is characterized by a temporal association of markers for inflammation and injury.

Entities:  

Keywords:  Acute tubule necrosis; Chronic on acute kidney injury; Ischemia/reperfusion injury; Necroinflammation; Renal scarring

Year:  2020        PMID: 32059667     DOI: 10.1186/s12929-020-0623-9

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  4 in total

1.  Angiotensin type 2 receptor activation limits kidney injury during the early phase and induces Treg cells during the late phase of renal ischemia.

Authors:  Riyasat Ali; Sanket Patel; Tahir Hussain
Journal:  Am J Physiol Renal Physiol       Date:  2021-03-15

2.  Integrated Analysis of the CircRNA-Based ceRNA Network in Renal Fibrosis Induced by Ischemia Reperfusion Injury.

Authors:  Lei Wei; Zhixiang Yu; Limin Liu; Ying Zhou; Xiao Bai; Liya Wang; Ming Bai; Shiren Sun
Journal:  Front Genet       Date:  2022-02-10       Impact factor: 4.599

3.  Analysis of mRNA and protein kidney injury Molecule-1 (KIM-1) expression in a kidney model during the initiation phase of ischemia reperfusion injury.

Authors:  Jerny Dase; Haerani Rasyid; Rina Masadah; Muhammad Husni Cangara; Agussalim Bukhari; Ressy Dwiyanti; Mochammad Hatta
Journal:  Ann Med Surg (Lond)       Date:  2022-02-11

4.  Combined Systemic Intake of K-ATP Opener (Nicorandil) and Mesenchymal Stem Cells Preconditioned With Nicorandil Alleviates Pancreatic Insufficiency in a Model of Bilateral Renal Ischemia/Reperfusion Injury.

Authors:  Asmaa Mohammed ShamsEldeen; Sarah A Abd El-Aal; Basma Emad Aboulhoda; Hend AbdAllah; Sara Mahmoud Gamal; Fatma E Hassan; Marwa Nagi Mehesen; Laila Ahmed Rashed; Abeer Mostafa; Nermeen Bakr Sadek
Journal:  Front Physiol       Date:  2022-06-23       Impact factor: 4.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.